Nanotherapeutics’ bone void filler receives expanded FDA 510(k) marketing clearance

Nanotherapeutics received expanded 510(k) marketing clearance from the U.S. Food and Drug Administration for use of NanoFUSE DBM in spinal fusion.

Advertisement
By: Staff

NanoFUSE DBM is the company’s proprietary bone void filler product. Specifically, it has been cleared for use with autograft as a bone graft extender in the posterolateral spine. It is the first off-the-shelf DBM product containing bioactive glass available for use in an orthopedic clinical setting.

More articles on devices:

Amedica brings on with PCG Advisory as agency of record
OrthoWorx commits $475k on workforce development — 6 initiatives
Mesoblast gets patent for mesenchymal precursor cell technology — 7 thing to know

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

A practical look at fixing radiology’s denial problem at the source

Recommended Whitepaper

Advertisement

Next Up in Spinal Tech

  • 20 key updates from 5 medtech titans

    From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

    By: Cameron Cortigiano

  • SurGenTec's ION-C cleared for navigation use

    SurGenTec’s ION-C earned FDA 510(k) clearance for ION-C navigation instruments with the ION-C posterior cervical facet fixation implant, according to…

    By: Carly Behm

  • VB Spine in the headlines: 6 updates

    VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

    By: Carly Behm
Advertisement

Comments are closed.